Actinium Pharmaceuticals (NYSE:ATNM – Get Free Report) is one of 1,026 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it contrast to its rivals? We will compare Actinium Pharmaceuticals to related businesses based on the strength of its risk, dividends, earnings, valuation, institutional ownership, analyst recommendations and profitability.
Valuation & Earnings
This table compares Actinium Pharmaceuticals and its rivals top-line revenue, earnings per share (EPS) and valuation.
Gross Revenue | Net Income | Price/Earnings Ratio | |
Actinium Pharmaceuticals | $81,000.00 | -$48.82 million | -1.10 |
Actinium Pharmaceuticals Competitors | $2.49 billion | $147.94 million | -4.34 |
Actinium Pharmaceuticals’ rivals have higher revenue and earnings than Actinium Pharmaceuticals. Actinium Pharmaceuticals is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Analyst Ratings
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Actinium Pharmaceuticals | 0 | 1 | 4 | 0 | 2.80 |
Actinium Pharmaceuticals Competitors | 7238 | 20179 | 47071 | 1106 | 2.56 |
Actinium Pharmaceuticals currently has a consensus target price of $11.40, indicating a potential upside of 506.38%. As a group, “Pharmaceutical preparations” companies have a potential upside of 61.31%. Given Actinium Pharmaceuticals’ stronger consensus rating and higher probable upside, research analysts clearly believe Actinium Pharmaceuticals is more favorable than its rivals.
Risk and Volatility
Actinium Pharmaceuticals has a beta of 0.14, meaning that its stock price is 86% less volatile than the S&P 500. Comparatively, Actinium Pharmaceuticals’ rivals have a beta of 0.85, meaning that their average stock price is 15% less volatile than the S&P 500.
Insider and Institutional Ownership
27.5% of Actinium Pharmaceuticals shares are held by institutional investors. Comparatively, 44.8% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 4.0% of Actinium Pharmaceuticals shares are held by company insiders. Comparatively, 14.0% of shares of all “Pharmaceutical preparations” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Profitability
This table compares Actinium Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Actinium Pharmaceuticals | N/A | -101.69% | -48.91% |
Actinium Pharmaceuticals Competitors | -3,638.22% | -299.82% | -32.35% |
Summary
Actinium Pharmaceuticals rivals beat Actinium Pharmaceuticals on 7 of the 13 factors compared.
Actinium Pharmaceuticals Company Profile
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company’s research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.
Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.